Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer
Yanmei Wu,1 Yu Zhang,2 Hao Pi,1 Yuan Sheng1 1Department of Breast and Thyroid Surgery, Changhai Hospital, Navy Medical University, Shanghai 200433, People’s Republic of China; 2Medical Affairs, Pfizer Biopharmaceutical Group, Shanghai 200041, People’s Republic of ChinaCorresponde...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-05-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/current-therapeutic-progress-of-cdk46-inhibitors-in-breast-cancer-peer-reviewed-article-CMAR |
id |
doaj-5eddcea9887d433ea78adf8378ec8fc3 |
---|---|
record_format |
Article |
spelling |
doaj-5eddcea9887d433ea78adf8378ec8fc32020-11-25T02:03:45ZengDove Medical PressCancer Management and Research1179-13222020-05-01Volume 123477348753785Current Therapeutic Progress of CDK4/6 Inhibitors in Breast CancerWu YZhang YPi HSheng YYanmei Wu,1 Yu Zhang,2 Hao Pi,1 Yuan Sheng1 1Department of Breast and Thyroid Surgery, Changhai Hospital, Navy Medical University, Shanghai 200433, People’s Republic of China; 2Medical Affairs, Pfizer Biopharmaceutical Group, Shanghai 200041, People’s Republic of ChinaCorrespondence: Yuan ShengDepartment of Breast and Thyroid Surgery, Changhai Hospital, Navy Medical University, Shanghai 200433, People’s Republic of ChinaEmail sheng528yuan@126.comAbstract: The clinical use of selective cyclin-dependent kinase (CDK) 4/6 inhibitors has significantly improved the prognosis of patients with hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (ABC/mBC), which almost achieved the double progression-free survival (PFS) in combination with endocrine therapy (ET) compared with ET alone. To date, there are 3 CDK4/6 inhibitors (palbociclib, ribocilcib and abemaciclib) approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) to treat patients with HR+/HER2-ABC/mBC in the first and later lines. The aim of this review is to summarize the current clinical use and ongoing clinical trials of CDK4/6 inhibitors, the published overall survival data, and the potential biomarkers and resistance to CDK4/6 inhibitors.Keywords: CDK4/6 inhibitor, breast cancer, mechanism, clinical efficacy, resistancehttps://www.dovepress.com/current-therapeutic-progress-of-cdk46-inhibitors-in-breast-cancer-peer-reviewed-article-CMARcdk4/6 inhibitorbreast cancermechanismclinical efficacyresistance |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Wu Y Zhang Y Pi H Sheng Y |
spellingShingle |
Wu Y Zhang Y Pi H Sheng Y Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer Cancer Management and Research cdk4/6 inhibitor breast cancer mechanism clinical efficacy resistance |
author_facet |
Wu Y Zhang Y Pi H Sheng Y |
author_sort |
Wu Y |
title |
Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer |
title_short |
Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer |
title_full |
Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer |
title_fullStr |
Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer |
title_full_unstemmed |
Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer |
title_sort |
current therapeutic progress of cdk4/6 inhibitors in breast cancer |
publisher |
Dove Medical Press |
series |
Cancer Management and Research |
issn |
1179-1322 |
publishDate |
2020-05-01 |
description |
Yanmei Wu,1 Yu Zhang,2 Hao Pi,1 Yuan Sheng1 1Department of Breast and Thyroid Surgery, Changhai Hospital, Navy Medical University, Shanghai 200433, People’s Republic of China; 2Medical Affairs, Pfizer Biopharmaceutical Group, Shanghai 200041, People’s Republic of ChinaCorrespondence: Yuan ShengDepartment of Breast and Thyroid Surgery, Changhai Hospital, Navy Medical University, Shanghai 200433, People’s Republic of ChinaEmail sheng528yuan@126.comAbstract: The clinical use of selective cyclin-dependent kinase (CDK) 4/6 inhibitors has significantly improved the prognosis of patients with hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (ABC/mBC), which almost achieved the double progression-free survival (PFS) in combination with endocrine therapy (ET) compared with ET alone. To date, there are 3 CDK4/6 inhibitors (palbociclib, ribocilcib and abemaciclib) approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) to treat patients with HR+/HER2-ABC/mBC in the first and later lines. The aim of this review is to summarize the current clinical use and ongoing clinical trials of CDK4/6 inhibitors, the published overall survival data, and the potential biomarkers and resistance to CDK4/6 inhibitors.Keywords: CDK4/6 inhibitor, breast cancer, mechanism, clinical efficacy, resistance |
topic |
cdk4/6 inhibitor breast cancer mechanism clinical efficacy resistance |
url |
https://www.dovepress.com/current-therapeutic-progress-of-cdk46-inhibitors-in-breast-cancer-peer-reviewed-article-CMAR |
work_keys_str_mv |
AT wuy currenttherapeuticprogressofcdk46inhibitorsinbreastcancer AT zhangy currenttherapeuticprogressofcdk46inhibitorsinbreastcancer AT pih currenttherapeuticprogressofcdk46inhibitorsinbreastcancer AT shengy currenttherapeuticprogressofcdk46inhibitorsinbreastcancer |
_version_ |
1724946075260813312 |